Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa
- PMID: 11735347
- DOI: 10.1006/mthe.2001.0498
Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa
Abstract
We designed experiments to evaluate the therapeutic potential of glial cell line derived neurotrophic factor (GDNF) to rescue photoreceptors from genetically determined cell death. Gene transfer of the neurotrophic factor to the retina was achieved via a recombinant adeno-associated virus (rAAV) vector containing the chicken beta-actin promoter/immediate early cytomegalovirus enhancer (CBA) driving the human GDNF gene. We delivered AAV-CBA-GDNF to the retinas of an animal model of retinitis pigmentosa, the TgN S334ter-4 rhodopsin line of transgenic rats. Immunohistochemical studies localized AAV-CBA-GDNF-derived recombinant protein to cell bodies, inner segments, and outer segments of photoreceptor cells as well as to retinal pigment epithelial cells. We assessed the effect of viral delivery by morphometric and electroretinographic analysis. These experiments showed that GDNF vector treatment leads to increased rod photoreceptor survival as indicated by morphometric analysis of outer nuclear layer thickness. AAV-CBA-GDNF-treated retinas also demonstrated functional improvement by the substantially increased amplitude of electroretinograms. AAV-CBA-GDNF delivery had a significant rescue effect on photoreceptor degeneration in this animal model.
Similar articles
-
Gene therapy for detached retina by adeno-associated virus vector expressing glial cell line-derived neurotrophic factor.Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3480-8. Invest Ophthalmol Vis Sci. 2002. PMID: 12407159
-
Two animal models of retinal degeneration are rescued by recombinant adeno-associated virus-mediated production of FGF-5 and FGF-18.Mol Ther. 2001 Apr;3(4):507-15. doi: 10.1006/mthe.2001.0289. Mol Ther. 2001. PMID: 11319911
-
Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2.Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3622-33. Invest Ophthalmol Vis Sci. 2000. PMID: 11006261
-
Range of retinal diseases potentially treatable by AAV-vectored gene therapy.Novartis Found Symp. 2004;255:179-88; discussion 188-94. Novartis Found Symp. 2004. PMID: 14750604 Review.
-
Mutation-Independent Gene Therapies for Rod-Cone Dystrophies.Adv Exp Med Biol. 2018;1074:75-81. doi: 10.1007/978-3-319-75402-4_10. Adv Exp Med Biol. 2018. PMID: 29721930 Review.
Cited by
-
Feline neural progenitor cells II: use of novel plasmid vector and hybrid promoter to drive expression of glial cell line-derived neurotrophic factor transgene.Stem Cells Int. 2012;2012:604982. doi: 10.1155/2012/604982. Epub 2012 Mar 20. Stem Cells Int. 2012. PMID: 22550512 Free PMC article.
-
Retinitis pigmentosa.Orphanet J Rare Dis. 2006 Oct 11;1:40. doi: 10.1186/1750-1172-1-40. Orphanet J Rare Dis. 2006. PMID: 17032466 Free PMC article. Review.
-
Targeted transgene expression in muller glia of normal and diseased retinas using lentiviral vectors.Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1844-52. doi: 10.1167/iovs.05-1570. Invest Ophthalmol Vis Sci. 2007. PMID: 17389520 Free PMC article.
-
Gene-agnostic therapeutic approaches for inherited retinal degenerations.Front Mol Neurosci. 2023 Jan 9;15:1068185. doi: 10.3389/fnmol.2022.1068185. eCollection 2022. Front Mol Neurosci. 2023. PMID: 36710928 Free PMC article. Review.
-
Transplantation of adipose derived stromal cells into the developing mouse eye.Acta Histochem Cytochem. 2010 Dec 29;43(6):123-30. doi: 10.1267/ahc.10015. Epub 2010 Dec 3. Acta Histochem Cytochem. 2010. PMID: 21245978 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous